Update on recommendations for use of herpes zoster vaccine

Morbidity and Mortality Weekly Report

Volumn 63, Issue 33, 2014, Pages 729-731

  Hales, Craig M ^a   Harpaz, Rafael ^a   Ortega Sanchez, Ismael ^a   Bialek, Stephanie R ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADVISORY COMMITTEE; ARTICLE; COST BENEFIT ANALYSIS; FOOD AND DRUG ADMINISTRATION; HERPES ZOSTER; HUMAN; IMMUNIZATION; LICENSING; MIDDLE AGED; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES;

ADVISORY COMMITTEES; COST-BENEFIT ANALYSIS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; IMMUNIZATION; LICENSURE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84906716155     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2008;57(No. RR-5).
2. CDC. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. MMWR 2011;60:1528.
3. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007;​ 82:1341–9.
4. Lin F, Hadler JL. Epidemiology of primary varicella and herpes zoster hospitalizations: the pre-varicella vaccine era. J Infect Dis 2000;​ 181:1897–905.
5. Schmader KE, Johnson GR, Saddier P, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and healthrelated quality-of-life measures in older adults. J Am Geriatr Soc 2010;58:1634–41.
6. Hoyert DL, Xu JQ. Deaths: preliminary data for 2011. Natl Vital Stat Rep 2012;61:26.
7. Kanaras J. Customer letter. Merck Sharp & Dohme Corp.; February 2012.
8. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis 2012;54:922–8.
9. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–84.
10. Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012;55:1320–8.
11. Merck Sharp & Dohme Corp. Zostavax: European public assessment reports—product information. London, UK: European Medicines Agency; 2013. Available at http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Product_Information/human/000674/WC500053462.pdf.
12. Ragozzino MW, Melton LJIII, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine 1982;61:310–6.
13. Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993–2006: evaluation of impact of varicella vaccination. Clin Infect Dis2011;52:332–40.
14. Hales CM, Harpaz R, Joesoef MR, Bialek SR. Examination of links between herpes zoster incidence and childhood varicella vaccination.Ann Intern Med 2013;159:739–45.
15. Ortega-Sanchez IR. Decision and cost-effectiveness analyses of herpes zoster vaccination in adults 50 years of age and older. [Presentation] Atlanta, GA: US Department of Health and Human Services, CDC; 2013. Available at http://www.cdc.gov/vaccines/acip/meetings/ downloads/slides-oct-2013/04-hzv-redacted-ortega-sanchez.pdf.